– USA, CA – REVA Medical, Inc. (ASX:RVA) today announced that Scott Huennekens, a recognized business executive in the medical device industry, has been appointed to its Board of Directors as a non-executive director.
Scott Huennekens most recently served as President and Chief Executive Officer of Volcano Corporation, a global leader in intravascular imaging for coronary and peripheral applications, from April 2002 to February 2015. During his tenure with Volcano, he successfully led the Company from a start-up, through a $54 million IPO in 2006, to its eventual acquisition by Royal Phillips for $1.2 billion earlier this year. Previously, he served as President and Chief Executive Officer of Digirad Corporation, a leading provider of diagnostic imaging solutions, from 2000 to 2002. He joined Digirad as a start-up in 1997 as Chief Operating Officer and was promoted to President and Chief Executive Officer in 2000. During his tenure he led the company from a pre-revenue stage through successful product commercialization. Prior to joining Digirad he held senior positions at Baxter International, Inc. in the Edwards Cardiovascular Division and the Novacor division.
Mr. Huennekens currently serves on the boards of EndoChoice, Sonendo, Scripps Translational Science Institute, and the Medical Device Manufacturers Association (MDMA). He received his Bachelor of Science in Business Administration from the University of Southern California and an MBA from Harvard Business School.
“We are extremely pleased to welcome Scott Huennekens to our Board,” said Bob Stockman, REVA’s Chairman and Chief Executive Officer. “Scott is a highly-respected and seasoned business leader with extensive experience transitioning companies from a development stage to successful commercialization. His insight will be extremely valuable as we move REVA’s Fantom bioresorbable scaffold through clinical trials toward CE Mark approval and eventual European product launch.”
About REVA
REVA is a development stage medical device company located in San Diego, California, USA, that is focused on the development, testing, and eventual commercialization of its proprietary bioresorbable stents, which are called “scaffolds” because of their temporary nature. The Company’s scaffolds are currently in clinical studies and have been developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or “resorb”) from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company’s initial intended commercial product, the FantomTM scaffold, has been designed to offer an ideal balance of thinness and strength, and distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require successful clinical trial results and regulatory approval before it can commercialize Fantom or any other products.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
